Literature DB >> 27291068

Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity.

Taku Fujimura1, Aya Kakizaki2, Sadanori Furudate2, Yumi Kambayashi2, Setsuya Aiba2.   

Abstract

Immunosuppressive tumor-associated macrophages (TAMs) promote an immunosuppressive environment in the tumor-bearing host, together with regulatory T cells (Tregs). TAMs compose cancer stroma in skin cancers including melanomas and non-melanomas. The majority of tumor-associated macrophages (TAMs) are alternatively activated M2 macrophages that favor tumor development, and they comprise one of the main populations of inflammatory cells in skin cancers. On the other hand, TAMs could be modulated into M1-type macrophages that suppress tumor growth by stimulating and recruiting Th1 and effector cells in the tumor sites. Therefore, TAMs are a target for immunotherapy in various cancers. In this review, we discuss the definition and suppressive mechanisms of TAMs, as well as their biological activities in tumor-bearing hosts to assess potential therapeutic strategies.
Copyright © 2016 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenetic factors; Chemokines; Immunosuppression; M2 polarization; Regulatory t cells; Tumor-associated macrophages

Mesh:

Substances:

Year:  2016        PMID: 27291068     DOI: 10.1016/j.jdermsci.2016.05.015

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  23 in total

1.  Differentiated State of Initiating Tumor Cells Is Key to Distinctive Immune Responses Seen in H-RasG12V-Induced Squamous Tumors.

Authors:  Michael A Podolsky; Jacob T Bailey; Andrew J Gunderson; Carrie J Oakes; Kyle Breech; Adam B Glick
Journal:  Cancer Immunol Res       Date:  2017-01-30       Impact factor: 11.151

2.  Pigmented Epithelioid Melanocytoma (Animal Types of Melanoma) on the Nose.

Authors:  Kentaro Ohuchi; Taku Fujimura; Yumi Kambayashi; Hisayuki Tono; Eika Ohtake; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2018-06-13

Review 3.  TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment.

Authors:  Mai Abdel Mouti; Siim Pauklin
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

4.  Alternatively Activated (M2) Macrophage Phenotype Is Inducible by Endothelin-1 in Cultured Human Macrophages.

Authors:  Stefano Soldano; Carmen Pizzorni; Sabrina Paolino; Amelia Chiara Trombetta; Paola Montagna; Renata Brizzolara; Barbara Ruaro; Alberto Sulli; Maurizio Cutolo
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

5.  M2-Polarized Macrophages Compose Lupus Vulgaris Arising from a Bacillus Calmette-Guérin Vaccination Site.

Authors:  Yota Sato; Taku Fujimura; Sadanori Furudate; Aya Kakizaki; Osamu Iizawa; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2016-07-19

Review 6.  Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research.

Authors:  Helena Kupcova Skalnikova; Jana Cizkova; Jakub Cervenka; Petr Vodicka
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

7.  The axis IL-10/claudin-10 is implicated in the modulation of aggressiveness of melanoma cells by B-1 lymphocytes.

Authors:  Elizabeth Cristina Perez; Patricia Xander; Maria Fernanda Lucatelli Laurindo; Ronni Rômulo Novaes E Brito; Bruno Camolese Vivanco; Renato Arruda Mortara; Mario Mariano; José Daniel Lopes; Alexandre Castro Keller
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

8.  Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.

Authors:  Yu-Chen Wang; Xi Wang; Jiaji Yu; Feiyang Ma; Zhe Li; Yang Zhou; Samuel Zeng; Xiaoya Ma; Yan-Ruide Li; Adam Neal; Jie Huang; Angela To; Nicole Clarke; Sanaz Memarzadeh; Matteo Pellegrini; Lili Yang
Journal:  Nat Commun       Date:  2021-06-10       Impact factor: 14.919

Review 9.  Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer.

Authors:  Taku Fujimura; Yumi Kambayashi; Yasuhiro Fujisawa; Takanori Hidaka; Setsuya Aiba
Journal:  Front Oncol       Date:  2018-01-23       Impact factor: 6.244

10.  Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.

Authors:  Taku Fujimura; Takanori Hidaka; Yumi Kambayashi; Sadanori Furudate; Aya Kakizaki; Hisayuki Tono; Akira Tsukada; Takahiro Haga; Akira Hashimoto; Ryo Morimoto; Takuhiro Yamaguchi; Tadao Takano; Setsuya Aiba
Journal:  Oncotarget       Date:  2017-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.